| Handbook of hydrocarbon and lipid microbiology T McGenity, JR Van Der Meer, V de Lorenzo Springer 552, 4716, 2010 | 735 | 2010 |
| SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection P Feuerstadt, TJ Louie, B Lashner, EEL Wang, L Diao, JA Bryant, M Sims, ... New England Journal of Medicine 386 (3), 220-229, 2022 | 266 | 2022 |
| Bacterial synthesis of PHA block copolymers EN Pederson, CWJ McChalicher, F Srienc Biomacromolecules 7 (6), 1904-1911, 2006 | 156 | 2006 |
| SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial BH McGovern, CB Ford, MR Henn, DS Pardi, S Khanna, EL Hohmann, ... Clinical Infectious Diseases 72 (12), 2132-2140, 2021 | 122 | 2021 |
| Physical and chemical changes in feather keratin during pyrolysis E Senoz, RP Wool, CWJ McChalicher, CK Hong Polymer Degradation and Stability 97 (3), 297-307, 2012 | 108 | 2012 |
| Investigating the structure–property relationship of bacterial PHA block copolymers CWJ McChalicher, F Srienc Journal of biotechnology 132 (3), 296-302, 2007 | 103 | 2007 |
| Solubility and degradation of polyhydroxyalkanoate biopolymers in propylene carbonate CWJ McChalicher, F Srienc, DP Rouse AIChE journal 56 (6), 1616-1625, 2010 | 43 | 2010 |
| RENEWABLE ACRYLIC ACID PRODUCTION AND PRODUCTS MADE THEREFROM S HARRIS, KA SPARKS, OP PEOPLES, Y SHABTAI, ... WO Patent App. PCT/US2013/044,671, 2013 | 23* | 2013 |
| SER-109: An Oral Investigational Microbiome Therapeutic for Patients with Recurrent Clostridioides difficile Infection (rCDI) S Khanna, M Sims, TJ Louie, M Fischer, K LaPlante, J Allegretti, ... Antibiotics 11 (9), 1234, 2022 | 21 | 2022 |
| Manufacturing process of SER-109, a purified investigational microbiome therapeutic, reduces risk of coronavirus transmission from donor stool C McChalicher, A Abdulaziz, SS Zhou, MJ Lombardo, B Hasson, ... Open Forum Infectious Diseases 9 (9), ofac448, 2022 | 8 | 2022 |
| Increased yields of phas from hydrogen feeding and diverse carbon fixation pathways TM Ramseier, CWJ McChalicher US Patent App. 13/830,296, 2013 | 6 | 2013 |
| Drugging the microbiome and bacterial live biotherapeutic consortium production CWJ McChalicher, JG Auniņš Current Opinion in Biotechnology 78, 102801, 2022 | 3 | 2022 |
| Green process for producing polyhydroxyalkanoates and chemicals using a renewable feedstock Z Zhang, CWJ McChalicher, J Van Walsem, OP Peoples, RP Eno, ... US Patent 9,663,791, 2017 | 3 | 2017 |
| Manufacturing processes of a purified microbiome therapeutic reduce risk of transmission of potential bacterial pathogens in donor stool CWJ McChalicher, MJ Lombardo, S Khanna, GJ McKenzie, EM Halvorsen, ... The Journal of Infectious Diseases 228 (10), 1452-1455, 2023 | 2 | 2023 |
| Fr572 24-WEEK EFFICACY AND SAFETY DATA FROM ECOSPOR-III, A PHASE 3 DOUBLE-BLIND, PLACEBO-CONTROLLED RANDOMIZED TRIAL OF SER-109, AN INVESTIGATIONAL MICROBIOME THERAPEUTIC FOR … L Korman, B Lashner, C Kraft, M Sims, EE Wang, K Brady, CB Ford, ... Gastroenterology 160 (6), S-368-S-369, 2021 | 2 | 2021 |
| Genetically Engineered Microorganisms for the Production of Poly-4-Hydroxybutyrate TM Ramseier, CWJ McChalicher, WR Farmer, Z Zhang, DE Chang, ... US Patent App. 14/386,728, 2015 | 2 | 2015 |
| Efficacy and Safety of Investigational Microbiome Drug SER-109 for Treatment of Recurrent Clostridioides difficile Infection B McGovern, M Sims, C Kraft, E Wang, K Brady, C Ford, MJ Lombardo, ... Antimicrobial Stewardship & Healthcare Epidemiology 1 (S1), s5-s5, 2021 | 1 | 2021 |
| Abstract CT030: Randomized placebo-controlled, biomarker-stratified phase 1b microbiome modulation trial for metastatic melanoma demonstrates impact of antibiotic pre … IC Glitza Oliva, YD Seo, CN Spencer, JR Wortman, EM Burton, FA Alayli, ... Cancer Research 84 (7_Supplement), CT030-CT030, 2024 | | 2024 |
| Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and Immunity IC Glitza, YD Seo, CN Spencer, JR Wortman, EM Burton, FA Alayli, ... Cancer Discovery, OF1-OF15, 2024 | | 2024 |
| WITHDRAWN: Manufacturing Process of Investigational Microbiome Therapeutic, SER-109, Reduces Risk of Bacterial Pathogen Transmission CWJ McChalicher, MJ Lombardo, S Khanna, GJ McKenzie, BH McGovern, ... Gastro Hep Advances, 2023 | | 2023 |
Tom RamseierRamseier Biotech ConsultingVerified email at metabolix.com
